Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ZI-PR-1
- Development stage
- Preclinical
- Lead developer
- Zelluna
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
ZI-PR-1 is a preclinical-stage T-cell receptor-engineered natural killer (TCR-NK) cell therapy being developed by Zelluna Immunotherapy for the treatment of solid tumors. The therapy targets the PRAME (PReferentially expressed Antigen in MElanoma) tumor antigen, which is frequently overexpressed in various cancers but has limited expression in healthy tissues. By engineering allogeneic natural killer cells from healthy donors to express specific TCRs, ZI-PR-1 combines the precise antigen recognition of T-cells with the innate anti-tumor activity and favorable safety profile of NK cells. This 'off-the-shelf' approach allows for large-scale manufacturing and on-demand administration, potentially overcoming the logistical and safety challenges associated with autologous CAR-T or TCR-T therapies.
- Other names
- ZI-PR-1-Zelluna Immunotherapy-PRAME-TCR-NK cell therapy-cell therapy-solid tumorsZI-PR1-Zelluna Immunotherapy-PRAME-TCR-NK cell therapy-cell therapy-solid tumorsZI-PR 1-Zelluna Immunotherapy-PRAME-TCR-NK cell therapy-cell therapy-solid tumors
02
Targets
PRAME peptide–HLA complex
Beyond the preview
Go deeper on ZI-PR-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZI-PR-1.